To evaluate the hematologic effects of recombinant human interleukin-6 (rhlL-6, Escherichia coli, SDZ ILS 969. IL-6). and determine its toxicity profile, we performed a phase I trial of IL-6 in 22 patients with various myelodysplastic syndromes (MDS), platelet counts <1OO,OOO/pL, and 4 % bone marrow (BM) blasts. Patients received one of four doses of IL-6 (1.0, 2.5, 3.75, and 5.0 pg/kg/d) as a subcutaneous injection on day 1, followed by a 7-day wash-out period, and then 28 days of IL-6 therapy. Dose-limiting toxicities of fatigue, fever, and elevated alkaline phosphatase were seen at 5.0 pg/kg/d; the maximum tolerated dose was 3.75 pg/kg/d. All patients experienced a t least grade II fever and all had an increase in acute phase proteins. Eight patients (36%) experienced at least a transient improvement in platelet counts; three fulfilled the criteria for response, whereas five others had clinically significant increases that failed t o meet response crite-HE MYELODYSPLASTIC syndromes (MDS) are a heterogeneous group of hematologic disorders characterized by ineffective hematopoiesis affecting one or more cell lineages.' Transformation to acute myeloid leukemia (AML) occurs in 10% to 90% of patients, and relates both to the French-American-British (FAB) classification (especially the percentage of bone marrow myeloblasts), and to the presence of cytogenetic abnormalities'.' or oncogene mutatiom4 The majority of patients with MDS eventually succumb to infectious or bleeding complications caused by granulocytopenia or thrombocytopenia, respectively.
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In addition to blood product support, therapy for MDS has included standard cytotoxic ~hemotherdpy,~.~ differentiationinducing therapy,"" and steroids."," These therapies rarely result in clinical remissions and are frequently associated with significant toxicities. Allogeneic bone marrow transplantation (BMT) is an option for younger patients, with ria. Various IL-6-related toxicities prevented more than three patients from receiving maintenance therapy. Two of the three patients who received maintenance IL-6 therapy had a persistent increase in platelet counts, during 3 and 12 months of IL-6 therapy, respectively. Laboratory studies indicated that IL-6 increased the frequency of higher ploidy megakaryocytes but did not significantly increase the number of assayable megakaryocytic progenitor cells, suggesting that IL-6 acts as a maturational agent rather than a megakaryocyte colony-stimulating factor. Although IL-6 therapy can promote thrombopoiesis in some MDS patients, its limited activity and significant therapy-related toxicity preclude its use as a single agent in this patient population. Further studies, combining low doses of IL-6 with other hematopoietic growth factors, are underway. 0 1995 b y The American Society of Hematology.
several studies demonstrating up to 50% disease-free survival after 2 to 3 years Unfortunately, only a minority of patients with MDS are suitable candidates for HLA-identical sibling allogeneic transplants.
A number of hematopoietic growth factors have been used to treat the cytopenias associated with MDS. Both granulocyte colony-stimulating factor (G-CSF) and granulocytemacrophage colony-stimulating factor (GM-CSF) induce an increase in peripheral blood (PB) neutrophil numbers of MDS patients, but neither induce significant multi-lineage respon~es.l'~~~ In several phase U11 studies, patients with cytopenias caused by MDS have also been treated with subcutaneously administered interleukin-3 (IL-3) at doses ranging from 250 to 500 pg/m2/d24 or 0.5 to 10 pgkgld." Increases in PB leukocyte counts were observed in most patients. whereas platelet and red blood cell (RBC) responses were seen in about one third of the patients.
IL-6 is a novel cytokine with pleiotropic activities that include the ability to stimulate B-cell differentiation and Ig production" and augment the generation of cytotoxic T lymphocytes (CTLs) by IL-2.27.28 IL-6 enhances the in vitro effects of IL-3 on hematopoietic progenitor cell^,'^^^" and stimulates thrombopoiesis.3'"5
In vitro experiments with IL-6 have shown its ability to enhance the maturation of megakaryocyte precursor^.^'.^^ IL-6 does not have a direct proliferative effect on megakaryocytic progenitor cells, in contrast to other in vitro multilineage factors such as GM-CSF or IL-3.3h,37 Preclinical animal data in mice" and nonhuman have demonstrated that IL-6 has potent thrombopoietic activity, which appears to be mediated via a maturational effect on megakaryocyte precursors. In addition to its hematopoietic effects, IL-6 is also a potent inducer of acute phase proteins including C-reactive protein, fibrinogen, and a2-macroglobulin. 4 
MATERIALS AND METHODS
Patient eligibility. Patients with thrombocytopenia associated with an MDS as classified by criteria established by the FAB Cooperative Group and with less than 5% BM blasts were eligible for enrollment if they met the following criteria: age 16 to 75 years; female patients practicing an approved method of birth control with a negative serum p-HCG pregnancy test (if appropriate); FAB classification of refractory anemia (RA), RA with ringed sideroblasts (RARS), or chronic myelomonocytic leukemia (CMMoL); thrombocytopenia (platelet count <lOO,OOO/pL) on three successive occasions within 2 to 4 weeks of study entry; a Karnofsky performance status greater than 60%; adequate hepatic and renal function (SGOT and alkaline phosphatase <3X upper limit of normal, total bilirubin <2x upper limit of normal, BUN <30 mg/dL, serum creatinine < 1.8 mgldL); no prior clinically significant cardiac or metabolic disease, human immunodeficiency virus infection, or hepatitis, and no prior BMT.
Patients with coagulopathies, active infections, a prior history of a lymphoproliferative disease, autoimmune disease, a chronic glomerulopathy, or an immunodeficiency disorder were excluded, as were those with extensive myelofibrosis on BM biopsy or BM failure caused by chemotherapy administered within 6 months of study entry. Patients were also ineligible if they had received chemotherapy, immunosuppressive or hormonal agents, or any other therapy for MDS within 4 weeks of study entry or had been treated with other cytokines within 8 weeks before entry. All patients were required to give written informed consent. The protocol was approved by the institutional review boards of the respective institutions which adhere to the principles of the Declaration of Helsinki.
Study medication. Escherichia coli-derived, nonglycosylated recombinant human IL-6 was provided by Sandoz Pharmaceuticals Corp (East Hanover, NJ) (SDZ ILS 969). Vials containing 150 or 750 pg of SDZ ILS 969 were reconstituted with I mL of sterile water for injection and administered by subcutaneous injection immediately after reconstitution. The specific activity of this IL-6 product was 6.1 x IO7 Ulmg of protein and contained 0. Cohorts of 4 to 6 patients received a single dose of IL-6 by subcutaneous injection at one of four dose levels (1.0, 2.5, 3.75, and 5.0 pg/kg/d) followed by a 7-day washout period (days 1 through 7). This period was termed cycle 0. After completion of cycle 0, patients received daily subcutaneous injections of IL-6 at their assigned dose level for 28 days (days 8 through 35) followed by a 14-day washout period (days 36 through 49). This latter period was termed cycle I and was used to determine the thrombopoietic effect of IL-6 in this patient population. Patients who showed a major or clinically significant minor response, as defined in the Clinical Response Criteria section below, were eligible for daily IL-6 maintenance therapy at their assigned dose for up to 1 year.
Standard criteria for dose escalation were used. Dose escalation was permitted if less than two patientslcohort experienced grade 111 or IV nonhematologic toxicity believed to be related to IL-6. If 2 patients in any cohort experienced grade I11 or IV nonhematologic toxicity, an additional two patients were added to that cohort. If 3 or more patients developed grade 111 or IV nonhematologic toxicity, an intermediate dosage level was added between that dosage level and the previously tolerated lower dosage level. The maximal tolerated dose (MTD) was one dose level below the level where three or more patients experienced grade I11 or IV nonhematologic toxicity. Patients experiencing a grade 111 or IV nonhematologic toxicity were removed from study. All toxicities were graded according to the Sandoz Toxicity Criteria pooled from Eastern Cooperative Oncology Group, Southwest Oncology Group, and National Cancer Institute parameters.
Evaluations. All patients underwent a thorough physical examination including vital signs and Kamofsky performance status before enrollment on the study. This evaluation was repeated at intervals throughout the dosing schedule. A chest radiograph and electrocardiogram were obtained at baseline, and at the end of each treatment cycle. Complete blood counts including a manual white blood cell (WBC) differential, absolute reticulocyte count, erythrocyte sedimentation rate were obtained at baseline, thrice weekly during cycles 0 and 1, and at varying intervals during the maintenance phase. Urinalysis, coagulation profiles, serum chemistries, and serum levels of acute phase proteins (C-reactive protein, fibrinogen, uansfemn, and a,-macroglobulin) were performed at baseline, at varying intervals during cycles 0 and l , and at each monthly maintenance therapy visit.
BM studies. BM aspirates and biopsies for morphology, megakaryocyte progenitors cell assays, and megakaryocyte ploidy analysis were performed at baseline, on day 29 of cycle 1, and at the end of each monthly maintenance period (morphology only). If 25% BM blasts were present on two successive examinations during the treatment period, IL-6 therapy was discontinued.
Megakaryocyte progenitor cell (CFU-MK) and ploidy assay system. BM aspirates were immediately diluted 1 : 1 with Iscove's Modified Dulbecco's Medium (IMDM) containing preservative-free sodium heparin (GIBCO-BRL, Grand Island, NY) at 20 U/mL and layered over an equal volume of Ficoll-Paque (specific gravity I .077 g/mL; Pharmacia Fine Chemicals, Piscataway, NJ)?7"2, 43 Density centrifugation was performed at 5OOg for 25 minutes at 4°C in a Beckman model TJ-6R centrifuge (Beckman Instruments, Fullerton, CA). The interface low-density BM (LDBM) mononuclear cells were collected and washed with IMDM containing no defined growth f a~t o r s .~~.~~.~' LDBM cells at a concentration of 2 X IO5 cellslplate were assayed for their ability to produce CFU-MK. The optimal concentrations of cytokines used for individual assays have been previously rep~rted.~'.~'.~~ Cultures were incubated for 12 days at 37°C in a 100% humidified atmosphere of 5% CO2 in air. After incubation, fibrin clots were fixed in situ, air dried, and stored frozen at -20°C until immunofluorescent staining was performed. Briefly, the mouse monoclonal IgC antibody IOE5, which recognizes the human platelet glycoprotein IIb-IIIa complex44 (supplied by Dr Bany S. Coller, Stony Brook, NY) was used to identify MKs.77.42.42 IOE5 was subsequently tagged with a fluoroscein-labeled, affinity-purified, goat-antimouse IgG(H + L) (Kirkegaard and Perry Laboratories, Inc, Gaithersburg, MD). The 35-mm Petri dishes were completely scanned at IOOX using an inverted microscope with a reflected light fluorescent attachment (Olympus Corporation, Lake Success, NY). A CFU-MK-derived colony was defined as a cluster of three or more fluorescent cells appearing after 12 days of i n c~b a t i o n .~~.~' ,~~ The data are reported as number of colonies per 2 X 10' mononuclear cells plated. Megakaryocyte ploidy analysis was performed based on an adaptation of the methods of Ishibashi et 3). The BM cells were subsequently separated by Percoll gradient centrifugation, washed in PBS, and incubated with propidium iodide (to label DNA) and monoclonal antibodies that recognize glycoprotein (GP) IIb/lIIa (CD 41) (Gentrak, Inc, Plymouth Meeting, PA). Negative controls consisted of mouse IgG,,-labeled 2N cells to determine a positive gate for megakaryocytes >2N. Positive controls consisted of cells labeled with anti-CD41 FITC which enable determination of those cells with >2N ploidy but having the epitope for GP IIb/IIIa. The Hewlett-Packard Consort 30 program was used to isolate cells based on FL2 (DNA content) and F L l (CD41 '). After 2N determination was completed, a range of 500 to 5,000 events (megakaryocytes) was analyzed, and markers were set between the nadirs and peaks to differentiate the various ploidy classes from 2N to 128N. The data are reported as a percentage of gated cells.
Serum recombinant human (rh) IL-6 neutralizing antibody. Serum samples were evaluated for the presence of anti-rhIL-6 antibodies by an enzyme-linked immunoabsorbent assay (ELISA). Serum samples were obtained at baseline, after completion of cycle I , and after each monthly maintenance period to look for the presence of antibodies to rhIL-6. Serum samples were stored at -70°C until analyzed. Before analysis, serum samples were heat-inactivated at 56°C for 30 minutes before testing. IL-6, at a final concentration of 5 pg/mL, was coated onto plastic ELISA 96-well microtiter plates (NUNC, Roskilde, Denmark) in pH 9.6 bicarbonate coating buffer overnight at 4°C. After adsorption of IL-6, the plates were washed three times (3X) with washing buffer (0.05% Tween 20 in TBS) and then were blocked with PBS/I% bovine serum albumin (BSA) (Sigma) for 1 hour at 37°C. Plates were then washed 3X with washing buffer, and were allowed to react for 1 hour at 37°C with a 1:lOO PBS/l% BSA/O.O5% Tween 20-diluted serum sample. Serum samples were analyzed in triplicate. A positive and negative monkey antiserum was always included in each assay. After washing (3X). the plates were reacted with a phosphatase-labeled goat-antihuman IgM + IgG + IgA (KPL Laboratory, MD) for 1 hour at 37°C. After further washing (3x), plates were incubated with p-NPP substrate at room temperature for 15 minutes. Color formation was monitored at 405 vrn (with reference wavelength at 650 vm) using a UVmax Microplate reader (Molecular Devices, Menlo Park, CA). If the optical density was 20.305, the serum sample was reconfirmed in a second, more specific assay.
This second assay was essentially the same as the above procedure with the exception that activity on the ELISA plate was compared in the presence and absence of IL-6. The difference between these values was used as the specific optical density. A patient's serum is only considered positive if it ( I ) yielded a specific optical density of >O. 157, and (2) this specific optical density was at least twofold greater than that of a pretreatment sample.
Clinicul response criteria. Clinical response was evaluated by comparing PB counts before, during, and after treatment with IL-6. For baseline platelet counts of s50,000/pL, a major response was defined as a >twofold increase over baseline; for pretreatment platelet counts of <50,OOO/pL, a major response was a =twofold increase to z50,000/pL. Patients who showed lesser degrees of thrombopoietic response were classified as minor responses if their platelet counts remained elevated for greater than one measurement, but failed to meet the above criteria. For absolute neutrophil counts (ANC) 2500 cells/FL at baseline, a clinical response was a twofold increase over baseline value; for pretreatment ANC values of <SO0 cells/&, a clinical response was a twofold increase over baseline value to >SO0 cells/pL. Erythrocyte transfusion requirements were also evaluated. A clinical response was defined as becoming transfusion independent from a baseline status of transfusion dependent or, in transfusion independent patients an increase of 2-2 g/dL over baseline hemoglobin value. Response criteria needed to be met for 2 2 serial evaluations.
Statistical analysis. Dose-limiting toxicity was defined by standard criteria based on the dose-escalation schema outlined above. Analysis of changes in serum chemistries, progenitor cell numbers. or acute phase proteins were performed using a two-sided Student's paired r-test. Results of hematologic parameters were reported as mean or median values. When appropriate, 95% confidence intervals were calculated and are presented.
RESULTS

Patient characteristics. Twenty-two patients with MDS
(RA, 19 patients; RARs, 2 patients; CMMoL, I patient) were accrued to this phase I trial, of whom 21 were found to be eligible for response and toxicity ( Toxicities. All patients experienced at least grade I1 fevers during their IL-6 therapy, and grade VI1 chills. fatigue, anorexia, headache, night sweats, and myalgias were common ( Table 2 ). The severity of the fever appeared to be doserelated. At the lower doses ( 5 2 . 5 pg/kg/d), fevers occurred approximately 4 to 6 hours after administration of IL-6 and pretreatment with acetaminophen or Trilisate (Purdue Frederick, Norwalk, CT) effectively alleviated the febrile response. At higher doses of rhIL-6, fevers often occurred within 30 to 60 minutes after IL-6 administration and were less easily controlled with these antipyretic medications.
There was no tachyphylaxis to the adverse events seen with IL-6.
One patient died during this study. This patient (patient 3020) discontinued IL-6 therapy on day 18 of cycle Abbreviations: KPS, Karnofsky performance status; v, yes; n, no; RBC Tx, red blood cell transfusion dependent; PLT Tx, platelet transfusion dependent; M, male; F, female; LD Ara-C, low-dose cytarabine; 6-TG, 6-thioguanine; PRD, prednisone; DEX, dexamethasone; CTX, cyclophosphamide; EPO. erythropoietin; ATG, antithymocyte globulin; NE, not evaluable.
are outlined in Table 3 . Grade 111 constitutional symptoms (fever, fatigue, chills, and myalgias) were seen in 3 of 4 patients treated at the 5.0 pgkgld dose level. Grade 111 elevated alkaline phosphatase was seen in the fourth patient at this dose level. These patients received between 3 and 17 days of IL-6 in cycle l before removal. After observation of dose-limiting toxicity at the 5.0 pgkg dose level, an intermediate dose of 3.75 pg/kg/d was investigated. This dose was determined to be the maximally tolerated dose, and 10 patients were accrued to this dosage level. Three of these 10 patients discontinued IL-6 because of grade 111 or IV adverse events (fever, fatigue, or anorexia). One patient at this dose level experienced a severe adverse event (grade 111 headache) but was not removed from the study, whereas another reported a severe rigor (not gradable) associated with grade I1 fever. A pericardial effusion and cardiac tamponade developed within 30 days of cessation of rhIL-6 therapy in one patient treated at a dose of 3.75 pg/kg/d. Effects on platelets. Eight patients experienced some increase in platelet counts during therapy with IL-6 in cycle 1, but only three were classified as major responders. All three had refractory anemia, and received doses of 3.75 pgl kg/d or greater. Their platelet responses are shown in Fig 1. The remaining five patients had platelet increases documented on greater than one occasion, but failed to meet the criteria for major response. One patient who experienced a minor response, became platelet transfusion independent during therapy with IL-6 (see Fig 2) . The mean of the two highest successive platelet counts, as well as the peak platelet counts, for all responding patients are listed in Table 4 . Although the three major responders were all treated at doses 23.75 pglkgld, three of the five minor responses occurred at the lowest dose level (1 pgkgld). Both major and minor responses were seen a median of 15 days into cycle l (range 7 to 29 days).
Three patients received treatment with IL-6 on the maintenance portion of the study at their assigned dose level. Two of these patients (both at 1 pglkgld) experienced modest prolonged thrombopoietic responses to IL-6 lasting 3 and 12 months, respectively. After cessation of IL-6 maintenance therapy, the patient's platelet counts returned to their pre- treatment levels. One patient (patient 1001) failed to respond to maintenance IL-6 therapy and was removed from study because of progression of his underlying disease (CMMoL).
The five other patients with minor responses did not go onto maintenance therapy either because they experienced doselimiting toxicity or refused treatment because of IL-6-related adverse events. Serum rhlL-6 neutralizing antibodies. Nine patients had paired serum samples available for anti-IL-6 antibody analysis and none developed detectable IL-6 antibodies by competitive ELISA.
Effects on WBCs and hemoglobin. Although WBC and neutrophil counts increased during IL-6 therapy (from a mean WBC of 6,400 t 6,300 cells/pL to 9,300 5 9,700 cells/pL and from a mean ANC of 3,500 +-4,300 cells/pL to 5,600 ? 6500 cells/pL), no true WBC or ANC responses were documented. PB leukocytes were predominantly lymphocytes in nearly all patients. Six patients had absolute neutropenia (ANC 5 1,000 cells/pL) before therapy with Pattern of minor platelet responses. A total of five patients experienced minor thrombopoietic responses to IL-6 therapy. Three of these patients were treated at the lowest dose level (1 pglkgld) (top) whereas three patients were treated at the MTD (3.75 pglkgl d) (bottom). Days on study start from initiation of treatment in cycle 0, through cycle 1 until the completion of the follow-up period (day 42). Patient 3017 received only 9 days of IL-6 therapy because of grade 111 fever.
rhIL-6 and no consistent improvement in peripheral neutrophil counts was seen in these patients. Monocyte counts did not significantly change during IL-6 therapy.
IL-6 was associated with a therapy-related, non-dosedependent anemia as has been seen in other studies!' N o patients who were previously transfusion-independent required RBC transfusions while receiving treatment with IL-6. All patients who were previously transfusion-dependent continued to require RBC transfusions during IL-6 therapy.
Effects of IL-6 on myeloblasts and BM. Two patients had increased numbers of BM blasts during therapy with IL-6. One patient with CMMoL (patient 1001), diagnosed 5 years before study entry, was treated at the 1 pg/kg/d dose level and had 10% blasts and promonocytes in his BM after For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From completion of cycle 1 of IL-6 (compared with a baseline of 5%). This patient had an increase in his platelet count from pretreatment values of 4,00O/pL to a maximum of 62,000/ pL on day 29 of cycle 1 with resolution of petechial hemorrhages. He received one cycle of maintenance therapy, but failed to show a thrombopoietic response. After his second 28-day maintenance course, BM evaluation revealed a further increase in the number of blasts and immature monocytes (to 20%) and the patient was removed from study. He remained stable for 3 months but died after transformation to acute leukemia. A second patient (patient 3020), with refractory anemia, was treated at the 3.75 pg/kg/d level and received 18 days of IL-6 in cycle 1 before being removed from study because of grade IV anorexia. BM aspiration after discontinuation of IL-6 showed 23% myeloblasts (her baseline blast count was 3%). The patient died 8 days after her last dose of IL-6 from sepsis and neutropenia, related to her underlying disease.
We evaluated BM morphology in all patients. No significant change in BM cellularity (mean pretreatment value of 54% ? 3 I % v mean posttreatment value of 45% ? 28%; P = not significant [NS]) nor in mye1oid:erythroid ratio was seen, comparing the pretreatment and posttreatment BM trephine biopsies and aspirates.
Blood chemistries. Renal and hepatic function did not change during the IL-6 therapy with the exception of the patient described above. A significant reduction in serum cholesterol levels was noted on day 2 of cycle 0 after a single injection of IL-6 (mean baseline cholesterol = 167.4 ? 57.04 mg/dL, 95% confidence intervals = 140.7 to 194.0 compared with mean day 2 value = 141.9 ? 43.9 mg/dL, 95% confidence intervals = 120.1 to 163.7; P = .0001). A mean reduction in serum cholesterol level of 35% was seen during IL-6 therapy (mean nadir cholesterol values = 1 l 1.1 ? 37.1 mg/dL, 95% confidence intervals = 94.3 to 128.0; P = .0025). Similar reductions in serum triglycerides were seen (mean baseline triglyceride value = 173.2 5 89.63 mg/ dL compared with mean day 2 value = 76 ? 38.71 mg/dL, P = .0OO1 and mean day 36 value = 109.6 -+ 68.04 mg/dL, P = .0014), but not all samples were obtained under fasting conditions. The effect of IL-6 on cholesterol and triglyceride levels was not dose-related, and generally persisted during the period of IL-6 therapy. Rapid reductions in serum albumin levels were also seen by day 2 of cycle 0 (mean baseline albumin = 4.1 t 0.33 compared with mean day 2 value 3.59 ? 0.38, P = .0001), possibly related to plasma volume expansion. No changes in serum calcium or phosphorus were seen during the study.
Acute phase proteins. Subcutaneous administration of IL-6 resulted in an increase in various acute phase proteins during cycles 0 and 1. The study patients had mildly elevated C-reactive protein (CRP) values at baseline (mean pre-treatment CRP = 1.43 mg/dL [95% confidence interval: 0.751 to 2.096]), which increased in response to treatment at all doses. Mean CRP values for patients treated at the MTD of 3.75 pg/kg/d are shown in Fig 3. A statistically significant increase in CRP was seen on day 10 (day 2 of cycle 1) ( P = .003), and CRP levels remained elevated through the course of therapy, returning to baseline levels within 7 days of cessation of IL-6. The time course of the increase in CRP values at the other dose levels was similar (data not shown). Baseline fibrinogen levels were within the normal range for all patients studied (mean baseline value = 280.7 ? 48.02). Fibrinogen concentrations were measured pretreatment, midway through cycle 1, and after completion of IL-6 therapy; statistically significant increases in fibrinogen levels were seen on day 19 (day 12 of cycle l ) (mean day 19 value = 355.9 5 125.86, P = .01). Other acute phase proteins such as transfenin (mean baseline value = 220.8 ? 49.17 mg/ dL) and a,-macroglobulin (mean baseline value = 215.3 884.76 mg/dL) were within the normal range at baseline and did not change significantly during the study.
Effects on megakaryocytic progenitor cells. We studied BM megakaryocyte progenitor numbers (BM Cm-MK) in 14 patients treated on this study; paired pretreatment and posttreatment samples were available from nine patients. The mean number of assayable BM CFU-MK for these 9 patients
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From was 11.67 t 11.6 (range 1.5 to 39.0) compared with 19.0 t 4.2 seen in normal BM. Due to multiple factors, progenitor cell assays were not able to be performed on the three major responders. Three of the nine patients (patients 2002, 1003, and 2019) showed treatment-related increases in BM CFU-MK numbers to near-normal levels (mean pretreatment value = 10.83 ? 7.0 to mean posttreatment value = 37.67 5 10.9, P = .018). This increase occurred during the 3 months of maintenance IL-6 therapy in one of these patients (patient 2002) (see Table 5 ). Interestingly, two of the three patients (patients 2002 and 1003) who showed increases in their BM CFU-MK numbers experienced prolonged thrombopoietic responses to IL-6 therapy. The remainder of the patients showed no significant change in their progenitor numbers (mean pretreatment value = 12.7 1 5 12.8 to mean posttreatment value = 5.23 t 1.9, P = .14). Of these seven patients, none obtained a clinically significant response.
We also studied the effects of IL-6 on megakaryocyte maturation by evaluating BM MK ploidy in 15 patients; paired samples were available from 14 of these patients. The number of low ploidy megakaryocytes at baseline (23.4% 2N and 18.3% 4N) was statistically significantly greater than that seen in normal BM (3.9% 2N and 3.0% 4N, P = .0001), consistent with the presence of micromegakaryocytes, which are associated with myelodysplastic syndromes. After treatment with IL-6, a statistically significant increase in the number of higher ploidy (232N) megakaryocytes was seen (mean pretreatment value = 12.5% ? 13.83% compared with mean posttreatment value = 19.7% t 15.7696, P = .027) (see Fig 4) . The mean modal ploidy both before and after treatment with IL-6 was 2N (pretreatment 2N content = 23.4% t 17.42% compared with posttreatment 2N content = 21.6% t 12.68%, P = NS). Five patients treated with IL-6 at 1 .O to 3.75 pgkgld had increases in modal ploidy following IL-6 therapy (median modal ploidy pretreatment = 4N, range 2N-8N compared with median posttreatment modal ploidy = 8N, range 4N to 32N). 
DISCUSSION
Morbidity and mortality in patients with myelodysplasia is often the consequence of progressive pancytopenia. Although transfusions of RBCs and prophylactic antibiotics can reduce morbidity from anemia and neutropenia, refractory thrombocytopenia is difficult to manage. Platelet transfusions, although effective initially, are frequently of limited long-term value because of the development of alloimmunization.""." ' We performed a phase I trial of a pleiotropic hematopoietic growth factor, IL-6, in an attempt to promote platelet production in patients with thrombocytopenia secondary to MDS. Dose-limiting toxicity (DLT) was seen at a dose of 5.0 pgkg/d and consisted of constitutional symptoms and elevation of alkaline phosphatase. The MTD in this study was 3.75 pgkg/d, though even at this dose 4 of 10 patients experienced serious adverse events related to the study drug. Of note is the fact that the doses tolerated in this study are significantly less than that observed in antitumor studies of IL-6 where doses of greater than 30 pgkgld have been admini~tered."'~' Similarly, in the postchemotherapy setting, doses up to 25 pgkgld have been administered without DLT.4' In patients receiving IL-6 after high-dose chemotherapy with BM reinfusion:' the MTD was 1.0 pgkgld with DLT of hyperbilirubinemia seen at 3.0 yg/kg/d. It is possible that patients with chronic BM failure states, or post BMT. could be more prone to toxicity from IL-6 because of higher circulating levels of other endogenous cytokines, such as tumor necrosis factor-a (TNF-a) or IL-1 . Although levels For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From of TNF-a have been previously reported to be elevated in patients with MDS," this hypothesis remains speculative.
The primary aim of our study was to determine the safety of IL-6 in a population of MDS patients with thrombocytopenia. Because patients with MDS have been shown to have a hematopoietic maturational defect which leads to their pancytopenia, it was hypothesized that IL-6 might correct these abnormalities and result in effective thrombopoiesis. Treatment of MDS patients with other hematopoietic growth factors, such as G-CSF and GM-CSF, results in increased production of myeloid-lineage cell^"^'^^*^ and our results show that IL-6 can increase platelet production in selected patients with MDS. This effect did not appear to be dose-related because three of the eight patients who showed a thrombopoietic effect were treated at the lowest dose level (including two patients with prolonged responses to continued IL-6 therapy). While the three major responders were treated at doses 23.75 pgkg/d, the constitutional symptoms seen at these doses precluded the prolonged administration of IL-6. Unfortunately, only one patient in our entire study experienced a significant response with tolerable side effects. One other patient, treated at the 1 pgkgld dose level, experienced a clinically significant minor response and became platelet transfusion independent. Among the nine patients evaluated for the development of anti-IL-6 neutralizing antibody after IL-6 therapy, none demonstrated detectable antibody. Because of the short duration of therapy in the majority of patients, it is unlikely that the development of a nonneutralizing anti-IL-6 antibody played a significant role in patient response to IL-6 treatment.
Although other IL-6 studies have shown what appears to be a dose-related increase in platelet counts:' IL-6 intolerance precluded us from exploring higher doses of IL-6. In this study constitutional symptoms, which were not lifethreatening, were dose-limiting. Because of the severe thrombocytopenia seen in our patients we were unable to use nonsteroidal anti-inflammatory agents to combat the doselimiting constitutional symptoms. Alternative schedules of IL-6 may result in less significant toxicity.
One of the difficulties in treating patients with MDS is the tremendous heterogeneity of the disease. All patients in this study were required to have less than 5% BM blasts before IL-6 therapy. Two patients showed an increase in the percentage of blasts in their BM possibly related to IL-6 therapy. This may represent a direct effect of IL-6 or the natural history of their underlying disease. One of these patients experienced a transformation to acute leukemia during IL-6 therapy, whereas the second patient had a long history of CMMoL but had a gradual transformation to leukemia that occurred during IL-6 maintenance therapy. Previous in vitro and preclinical in vivo studies evaluating the effect of IL-6 on leukemic blasts have shown that while IL-6 exerts a differentiational effect on myeloid leukemic cells, it does not appear to be proliferative." Although transformation to leukemia during hematopoietic growth factor therapy usually occurs in patients with 2 15% blasts, the rate of transformation in this study appears to be similar to that seen in other phase I studies of hematopoietic growth factors in Although two patients who had been treated on this study suffered hemorrhagic complication, both occurred at least 30 days beyond completion of IL-6 therapy. No other bleeding or thrombotic complications were seen associated with IL-6 therapy. Because of the severe baseline thrombocytopenia (platelet count <50,OOO/pL) seen in 19 of our 22 patients, formal evaluation of platelet function studies could not be effectively performed. Although studies by other investigators have suggested that IL-6 may act to enhance platelet function,'*.'' we were unable to evaluate this.
IL-6 has been associated with a therapy-related anemia in other st~dies,4','~ and although we saw a decrease in hemoglobin concentration, we were unable to detect a significant effect on transfusion requirements. Although we did not evaluate plasma volume changes in our patients, other investigators have shown that increased plasma volume is the reason for the anemia associated with this ~ytokine.'~ In contrast to patients with aplastic anemia treated with IL-6," no MDS patient became newly RBC transfusion-dependent as a result of IL-6 therapy. Variable and inconsistent changes in reticulocyte counts and no significant change in BM erythroid activity were seen. Additionally, no significant changes were seen in WBCs or WBC subsets including neutrophils or monocytes.
Preclinical models have shown that IL-6 therapy results in an increase in various acute phase proteins, secondary to the known hepatocyte stimulatory effects of this agent4" We observed an increase in CRP and fibrinogen levels but not transferrin or a,-macroglobulin. We also observed IL-6-induced decreases in cholesterol and triglyceride levels; the mechanism involved is not known.
Although IL-6 has previously been shown to stimulate the proliferation of primitive hematopoietic progenitor cell^,^^^'^ preclinical studies in nonhuman primates have not demonstrated a proliferative effect on megakaryocyte progenitor cells (Cm-MK)." In contrast, IL-6 is a potent inducer of megakaryocyte maturation, resulting in increases in megakaryocyte size and ploidy. 39 We evaluated BM megakaryocyte ploidy as well as the numbers of BM CFU-MK before and after treatment with IL-6. In the majority of patients, treatment with IL-6 induced maturation of MKS as determined by increases in MK ploidy. Although the maturational effect of IL-6 was seen in most patients, not all patients showed an associated thrombopoietic effect. Ploidy analysis in two of the three patients who were classified as major responders demonstrated significant increases in MK ploidy and in modal ploidy. In addition, all responding patients for whom paired samples were available, showed increases in MK ploidy. This suggests that the thrombopoietic activity of IL-6 is primarily mediated by its maturational effects on BM MKS. Unfortunately, most of the responses seen were MDS.17. 19.24 For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From transient in nature, suggesting that other aspects of thrombopoiesis are important for continued response.
Nearly all patients had low pretreatment levels of BM CFU-MK. In two patients the number of BM MK progenitors normalized after treatment with IL-6. Both of these patients were minor responders who maintained their thrombopoietic response to IL-6 therapy during the maintenance phase of the protocol. This supports the concept that normal levels of CFU-MK may allow IL-6 to promote a prolonged thrornbopoietic effect. The inability of MDS patients to generate an IL-6-sensitive pool of progenitors may be one reason why only a subset of patients responded. It is also possible that the timing of our BM evaluations (after 28 days of IL-6), prevented us from identifying additional significant changes in either MK progenitor number or MK ploidy. Addition of a second hematopoietic growth factor, which may increase the number of CFU-MKS, may allow IL-6 to exert greater thrombopoietic effects.
The three major responding patients received doses of IL-6 that generated unacceptable toxicity, precluding them from receiving maintenance therapy. Of the minor responders, three patients (all at the 1.0 ,ug/kg/d dose level), continued on maintenance therapy for 1, 3, and 12 months because of clinically significant thrombopoietic IL-6 effects. Two of the three patients experienced more lengthy responses to IL-6 treatment including patient 2002, who remained platelettransfusion independent while on therapy. Neither patient suffered any untoward effects from the chronic administration of IL-6, suggesting that long-term administration of this drug can be performed. Patient 1003 discontinued his maintenance therapy, because he suffered primarily from anemia and he did not perceive a clinical benefit from continued therapy.
In conclusion, we have shown that the MTD of 1L-6 is 3.75 pg/kg/d in the MDS population, substantially lower than the MTD in patients with normal hematopoiesis or postchemotherapy. This may be related to elevated endogenous circulating cytokine levels, although this needs to be specifically studied. Although IL-6 has the ability to enhance platelet production in this patient population only a small number of these responses are durable with continued therapy. The thrombopoietic effect of IL-6 appears to be mediated by its maturational effect on BM megakaryocytes. New schedules, doses, or combinations of IL-6 with other hematopoietic growth factors need to be studied to reduce toxicity and take advantage of potentially synergistic interactions.
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